8-K: Acasti Pharma Rebrands as Grace Therapeutics, Shifts Focus to GTx-104

Acasti Pharma Inc. is changing its name to Grace Therapeutics, effective October 28, 2024, and will trade under the ticker symbol GRCE, reflecting a renewed focus on its lead drug candidate, GTx-104.

Summary

• Acasti Pharma Inc. is changing its corporate name to Grace Therapeutics, Inc., effective October 28, 2024.
• The company's common stock will begin trading under the new ticker symbol GRCE on the Nasdaq, also effective October 28, 2024.
• The name change reflects the company's roots and its focus on scientific innovation, particularly the development of GTx-104.
• Grace Therapeutics is advancing GTx-104, a novel injectable formulation of nimodipine for aneurysmal subarachnoid hemorrhage (aSAH).
• The company has completed enrollment for the STRIVE-ON trial for GTx-104 and anticipates a data readout in early calendar 2025.
• A New Drug Application (NDA) submission to the FDA is expected in the first half of calendar 2025.
• The company has restructured to an agile biopharma model, rebuilt its management team, and strengthened its balance sheet.
• A virtual Key Opinion Leader (KOL) event on GTx-104 is scheduled for November 20, 2024.
• The addressable market for GTx-104 in the United States is estimated to be about $300 million.
• The development of GTx-102 and GTx-101 has been deprioritized in favor of GTx-104, but may be licensed or sold.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook with the rebranding and focus on GTx-104, but also acknowledges the inherent risks in drug development. The sentiment is optimistic but tempered with realism.

Positives

• The company is refocusing on its lead asset, GTx-104, which addresses a significant unmet medical need.
• The company has completed enrollment for the STRIVE-ON trial, indicating progress in clinical development.
• The company anticipates a data readout in early 2025 and an NDA submission in the first half of 2025, suggesting a clear path to potential commercialization.
• The company has restructured to an agile biopharma model, which may improve efficiency and responsiveness.
• The company has strengthened its balance sheet, which may provide financial stability.
• The company has re-domiciled to the United States, which may increase its attractiveness to investors.
• GTx-104 has shown significantly lower pharmacokinetic variability compared to oral nimodipine in trials.
• GTx-104 has the potential to better manage hypotension in aSAH patients.

Negatives

• The development of GTx-102 and GTx-101 has been deprioritized, which may impact the company's pipeline diversity.
• The company is dependent on the success of GTx-104, which introduces a concentration risk.

Risks

• The success and timing of regulatory submissions for GTx-104 are uncertain.
• Regulatory requirements or developments could impact the outcome and timing of the NDA application.
• Changes to clinical trial designs and regulatory pathways could affect the development timeline.
• Legislative, regulatory, political, and economic developments could impact the company's operations.
• Actual costs associated with clinical trials may differ from management's expectations.
• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company anticipates a data readout from the STRIVE-ON trial in early 2025 and plans to submit an NDA to the FDA in the first half of 2025. The company also believes that its U.S. corporate structure should increase its attractiveness to potential strategic partners and global institutional investors.

Management Comments

• The Grace Therapeutics brand reconnects us to our roots that are steeped in scientific innovation and highlights our transformative journey, said Prashant Kohli, CEO of Acasti.
• We have continued to make significant progress in the clinical development plan of GTx-104, including full enrollment of the STRIVE-ON trial and anticipate a data readout in early calendar 2025 with an expected submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of calendar 2025.
• We are proud of the progress made within a relatively short timeframe and look forward to fully realizing the Company's value under the Grace Therapeutics brand.

Industry Context

This announcement reflects a strategic shift for Acasti, now Grace Therapeutics, to focus on its most promising asset, GTx-104, in the competitive biopharmaceutical landscape. The company's move to rebrand and prioritize a specific drug candidate is a common strategy in the industry to streamline operations and maximize potential returns.

Comparison to Industry Standards

• The focus on a single lead asset, GTx-104, is similar to other biopharma companies that concentrate resources on their most promising drug candidates, such as companies like BioMarin Pharmaceutical Inc. which focuses on rare disease treatments.
• The estimated $300 million addressable market for GTx-104 is a significant opportunity, comparable to other niche market drugs targeting rare diseases.
• The timeline for data readout and NDA submission is typical for late-stage clinical trials, aligning with industry standards for drug development.
• The company's restructuring to an agile biopharma model is a common practice to improve efficiency and reduce costs, similar to strategies employed by companies like Amgen and Regeneron.

Stakeholder Impact

• Shareholders will see a change in the company's name and ticker symbol.
• The company's focus on GTx-104 may increase the potential for future value creation.
• Employees will be working under a new company name and brand.
• Customers and patients may benefit from the development of GTx-104.
• Potential strategic partners and global institutional investors may find the company more attractive due to its U.S. corporate structure.

Next Steps

• The company will complete the corporate name change to Grace Therapeutics on October 28, 2024.
• The company will begin trading under the ticker symbol GRCE on October 28, 2024.
• The company will host a virtual Key Opinion Leader event on November 20, 2024.
• The company will continue to advance the clinical development of GTx-104.
• The company anticipates a data readout from the STRIVE-ON trial in early 2025.
• The company plans to submit an NDA to the FDA in the first half of 2025.

Key Dates

Keywords

Grace Therapeutics, Acasti Pharma, GTx-104, nimodipine, aSAH, aneurysmal subarachnoid hemorrhage, NDA, FDA, clinical trial, biopharma